- $175.81m
- $169.06m
- $113.83m
Annual income statement for inTest, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 84.9 | 117 | 123 | 131 | 114 |
| Cost of Revenue | |||||
| Gross Profit | 41.2 | 53.4 | 57 | 55.4 | 48.9 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 76.4 | 106 | 113 | 127 | 118 |
| Operating Profit | 8.46 | 10.7 | 10.4 | 3.39 | -3.73 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 8.4 | 10.1 | 11 | 3.45 | -3.22 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 7.28 | 8.46 | 9.34 | 2.89 | -2.53 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 7.28 | 8.46 | 9.34 | 2.89 | -2.53 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 7.28 | 8.46 | 9.34 | 2.89 | -2.53 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.685 | 0.838 | 0.832 | 0.284 | -0.118 |